News

A total of approximately 395.7 million shares of Genentech common stock were tendered representing 84.7% of Genentech’s publicly held shares. Roche Investments USA has accepted for payment all

Caldera’s products include the Desara sling system for treating stress urinary incontinence. Encision will use its sales employees to supplement Caldera’s sales team in introducing Caldera’s products to

According to IH Systems, Robotic IV Automation (RIVA) system is a self-contained unit for filling IV syringes and bags. Kevin McGarry, CEO of IH Systems, said: “We are

Eli Lilly and Company has reported promising new data from Phase III Next trial which showed that arzoxifene, an investigational selective estrogen receptor modulator, was superior to raloxifene

For the year ended December 31, 2008, the company reported a net loss of $28.15 million, or $1.42 per share, compared to a net loss of $28.1 million,

The company reported net revenues of C$2 million for the first quarter of 2009, compared to C$599,000 for the same period of 2008. Luc Tanguay, senior executive vice

Zemiva is a molecular imaging radiopharmaceutical the company is developing to detect cardiac ischemia, the lack of sufficient blood flow to the heart. In this trial, the combination

Attract-1 has been enrolling patients in a variety of other countries since it began in April 2008. Extension of the trial to Japan follows the successful completion of

According to the company, Soar Dynamic Screening demonstrates a new approach to healthcare by providing men a detailed analysis of their prostate health based on several factors beyond